AnteoTech (ADO) Investor presentation summary

Financial position and business momentum

• Maintains a $3.3 million cash position with no debt and an R&D tax rebate claim in progress.

• Record levels of product samples are under evaluation by customers, indicating strong commercial momentum.

• Multiple near-term catalysts identified across both Life Sciences and Advanced Battery Technologies.

Strategic execution and market expansion

• Focused on targeted sales growth, strategic partnerships, and expanding the customer base in India, USA, South Korea, Japan, and Europe.

• Secured a five-year US$1.8 million contract with Serum Institute of India and initiated prototype ELISA product testing.

• Local business development resources engaged in India and new distributor relationships established in Japan and the USA.

Life Sciences advancements

• Collaborative CLIA product development underway with a major global life sciences company, showing reproducibility and performance improvements.

• AnteoBind NXT activation offers up to 1.8x stronger CLIA signals, 6x faster activation, and 6x lower antibody usage.

• Published technical white paper demonstrates cost and performance advantages over Tosyl-activated particles.

• Engaged with 50 top Indian IVD manufacturers and multiple companies are testing new ELISA plates.